Clinical Trial Update: Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating PTW-002 in patients with dominant or recessive dystrophic epidermolysis bullosa caused by COL7A1 exon 73 mutations. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa

Drugs mentioned

• PTW-002

Snippet

Sponsor: Phoenicis Therapeutics | Conditions: Dystrophic Epidermolysis Bullosa | Phase 1, Phase 2 | Status: UNKNOWN